Loading company…
Nanjing-based Xinrui Regeneration develops drugs for tissue regeneration, fibrosis reversal and tumor cell reprogramming.
Established in 2019 in Nanjing, China, Xinrui Regeneration develops drugs using its CReDIT small molecule discovery platform, which combines cell reprogramming, high-throughput genomics and artificial intelligence. Founder and Chief Scientist Officer Yang Zhao is a researcher and doctoral director at the Institute of Molecular Medicine, Peking University Institute of Future Technology, and the team comes from several leading Chinese universities. The company raised CNY 10 million in pre-Series A funding in January 2022 and formed a partnership with Suzhou Huace Bio in December 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in